US FDA approves IASO Bio's IND application for equecabtagene autoleucel for two new autoimmune disease indications
IASO Biotherapeutics (IASO Bio), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced that the investigational new drug (IND) application for its …